Case Katherine B, Allen Pamela B
Emory University School of Medicine, Atlanta, GA, USA.
Department of Hematology, Winship Cancer Institute, Atlanta, GA, USA.
Curr Hematol Malig Rep. 2025 Jan 13;20(1):5. doi: 10.1007/s11899-024-00746-7.
Cutaneous T cell lymphomas (CTCLs) are comprised of a heterogenous group of non-Hodgkin lymphomas that can be difficult to treat and are often refractory to standard therapies. Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common subtypes, accounting for the majority of CTCLs. There is no standard of care, and no treatments are curative. In this review, we summarize the promising, recently reported data describing novel systemic agents for the management of MF/SS.
Clinical trials are currently exploring a number of agents, including novel chemotherapies, antibodies and antibody drug conjugates (ADCs), immunotherapy, and cellular therapies. These promising novel agents may expand the treatment landscape for MF/SS.
皮肤T细胞淋巴瘤（CTCL）是一组异质性非霍奇金淋巴瘤，治疗困难，对标准疗法往往耐药。蕈样肉芽肿（MF）和塞扎里综合征（SS）是最常见的亚型，占CTCL的大多数。目前尚无标准治疗方案，也没有治愈性疗法。在本综述中，我们总结了近期报道的关于治疗MF/SS的新型全身用药的有前景的数据。
目前临床试验正在探索多种药物，包括新型化疗药物、抗体及抗体药物偶联物（ADC）、免疫疗法和细胞疗法。这些有前景的新型药物可能会拓宽MF/SS的治疗前景。
